In people with Graves' disease treated with medication, hyperthyroidism often returns over time—nearly 8 out of 10 patients experience it again after 10 years—and those with larger thyroid glands or still-positive thyroid-stimulating antibodies at the end of treatment are more likely to relapse.
Claim Context
Among patients with Graves' disease treated with antithyroid drugs, the probability of hyperthyroidism relapse increases over time, reaching 78.9% after 10 years, with larger goiter size and persistent thyroid-stimulating immunoglobulin (TBII) positivity at treatment end being strongly associated with higher relapse risk.
“Los resultados mostraron una probabilidad de recidiva del hipertiroidismo del 42,9% al año, del 59,8% a los 3 años, del 67,9% a los 5 años y del 78,9% a los 10 años. El tamaño del bocio se correlacionó muy significativamente con la probabilidad de recidiva (p < 0,0001)... sólo la positividad de los TBII al final del tratamiento influyó de forma muy significativa (p < 0,05).”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review of multiple high-quality cohort and RCT studies would establish whether goiter size and TBII positivity consistently predict relapse across diverse populations and treatment protocols, quantifying their independent predictive value.
A systematic review and meta-analysis of all prospective cohort studies and randomized trials evaluating Graves' disease patients treated with antithyroid drugs, stratifying relapse risk by baseline goiter size (classified by ultrasound volume) and TBII levels at treatment end, adjusting for age, sex, treatment duration, and antibody type, with pooled hazard ratios and I² statistics for heterogeneity.
An RCT could test whether reducing goiter size or suppressing TBII during treatment improves remission rates, establishing whether these factors are modifiable predictors of outcome.
A multicenter double-blind RCT of 500 adults aged 18–65 with newly diagnosed Graves' disease and goiter >40 mL, randomized to standard antithyroid drug therapy versus standard therapy plus adjunctive thyroxine or rituximab to suppress TBII, with primary outcome of sustained remission at 5 years defined as euthyroidism without medication and TBII <1.5 IU/L.
A prospective cohort study with standardized measurements of goiter volume and TBII levels at diagnosis and treatment end could quantify the independent contribution of each factor to relapse risk over time.
A prospective multicenter cohort of 1000 adults with Graves' disease, measured for goiter volume by ultrasound and TBII levels at diagnosis, during treatment, and at drug discontinuation, followed for 10 years with annual thyroid function tests, adjusting for age, sex, treatment duration, and smoking status using multivariable Cox regression.
A case-control study could compare prior exposures or biomarker levels between patients who relapsed and those who remained in remission to identify potential risk factors.
A matched case-control study of 300 patients with Graves' disease: 150 with relapse within 5 years of drug withdrawal and 150 matched controls (age, sex, treatment duration) who remained euthyroid, comparing baseline goiter volume, peak TBII levels, HLA haplotypes, and smoking history using conditional logistic regression.
A cross-sectional study could estimate the prevalence of large goiter and TBII positivity among patients with established relapse, but cannot determine if these preceded the relapse.
A cross-sectional survey of 500 patients with known Graves' disease relapse, measuring current goiter volume and TBII levels to determine if these markers remain elevated after relapse, compared to a control group of patients in remission.